Photo by finnnyc from unsplash
Programmed cell death protein‐1 (PD‐1) inhibitors synergize apatinib for anti‐tumour effect by regulating tumour microenvironment, vascular endothelial growth factor, hypoxia condition, immune response, etc. This study aimed to investigate the… Click to show full abstract
Programmed cell death protein‐1 (PD‐1) inhibitors synergize apatinib for anti‐tumour effect by regulating tumour microenvironment, vascular endothelial growth factor, hypoxia condition, immune response, etc. This study aimed to investigate the treatment efficacy and safety of camrelizumab (PD‐1 inhibitor) plus apatinib as third‐line or above therapy in metastatic colorectal cancer (mCRC) patients.
Keywords:
line therapy;
third line;
plus apatinib;
safety camrelizumab;
therapy metastatic;
efficacy safety
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!